Other formats:
BibTeX
LaTeX
RIS
@misc{1837977,
author = {Taylor, Joe and Shaw, Bridget and et, Al.},
address = {London},
edition = {NA},
keywords = {relapsed rhabdomyosarcoma; children; clinical study; FaR-RMS},
language = {eng},
location = {London},
publisher = {Far-RMS},
title = {An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma},
url = {https://clinicaltrials.gov/ct2/show/NCT04625907},
year = {2021}
}
TY - GEN
ID - 1837977
AU - Taylor, Joe - Shaw, Bridget - et, Al.
PY - 2021
TI - An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma
VL - NA
PB - Far-RMS
CY - London
KW - relapsed rhabdomyosarcoma
KW - children
KW - clinical study
KW - FaR-RMS
UR - https://clinicaltrials.gov/ct2/show/NCT04625907
N2 - FaR-RMS is an over-arching study for patients with newly diagnosed and relapsed RMS including multi-arm, multi-stage questions with three principal aims. These are to evaluate:•systemic therapy through the introduction of new agent regimens in the most advanced disease states: Very High Risk (VHR), High Risk (HR) and Relapse•the duration of maintenance therapy•radiotherapy to improve local control in VHR, HR and Standard Risk (SR) patients and to treat metastatic diseaseIn addition the study will evaluate:•risk stratification through the use of PAX-FOXO1 fusion gene status instead of histological subtyping•the use of FDG PET-CT response assessment as a prognostic biomarker for outcome following induction chemotherapy FaR-RMS includes a study entry point where all patients with RMS may give consent for the analysis of their biological samples and tumour pathology, alongside the collection of very basic patient characteristics, a treatment summary, and follow-up data for events.
ER -
TAYLOR, Joe, Bridget SHAW and Al. ET. \textit{An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma}. NA. London: Far-RMS, 2021, 29 pp. NA.
|
